- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00848939
Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis (DISTOL-PK)
October 19, 2012 updated by: United Therapeutics
An Evaluation of the Pharmacokinetics and Safety of Fixed and Escalating Doses of Oral Treprostinil Diethanolamine (UT-15C) Sustained Release Tablets in Patients With Systemic Sclerosis
This study will assess the pharmacokinetic and safety profile of treprostinil following fixed and escalating doses of treprostinil diethanolamine SR tablets.
Open-label, two-part study assessing the pharmacokinetics, safety, and tolerability of oral treprostinil diethanolamine SR.
Cohort 1: single 1 mg treprostinil diethanolamine SR dose.
Cohort 2: escalating doses of treprostinil diethanolamine SR up to a target dose of 4 mg BID.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Johns Hopkins Scleroderma Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Boston University School of Medicine Rheumatology Arthritis Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48016
- University of Michigan Scleroderma Program
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject gives voluntary written informed consent to participate in the study.
- Subject has been diagnosed with systemic sclerosis (SSc) as defined by American College of Rheumatology (ACR) criteria.
- Males and females age greater than 18 years at time of Screening.
- Presence of active digital ulcer OR history of digital ulcer occurring within past 6 months at time of Screening and poorly controlled Raynaud's phenomenon (as documented by patient report of 6-10 episodes per week).
- Females of childbearing potential must be willing to use two forms of medically acceptable contraception (at least one barrier method) and have a negative pregnancy test at Screening, confirmed at Baseline if separate visits. Women who are surgically sterile or have been post-menopausal for at least 2 years are not considered to be of child-bearing potential.
- Subject agrees to abstain from consuming grapefruit containing food or beverages for 3 days prior to Baseline and until discharge from the study.
- Subject is able to communicate effectively with study personnel and be considered reliable, willing and cooperative in terms of compliance with the protocol requirements.
Exclusion Criteria:
- Has diagnosis of pulmonary arterial hypertension and receiving approved or investigational therapies for PAH, including endothelin receptor antagonists, phosphodiesterase inhibitors, or prostacyclin analogues.
- Body weight less than 40 kg at time of Screening, confirmed at Baseline.
- The subject has a history of postural hypotension, unexplained syncope, a blood pressure that is less than 85 mmHg systolic or 50 mmHg diastolic at Screening or Baseline.
- Hemoglobin concentration less than 75% of the lower limit of the normal range at time of Screening.
- AST and/or ALT concentrations greater than 3 times upper limit of normal (ULN) at time of Screening.
- Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C.
- Intractable diarrhea, severe malabsorption, defined as greater than 15% unintentional loss of body weight in the last 6 months prior to Screening, or any severe organ failure (e.g., lung, kidney) or any life-threatening condition.
- Pregnancy or breast-feeding.
- Overlap with another connective tissue disease that could affect rest pain and hand function (e.g. diabetes mellitus, rheumatoid arthritis).
- Sympathectomy of the upper limb performed within 12 months of Baseline.
- Receipt of parenteral prostanoid treatment (epoprostenol, treprostinil sodium, or other prostacyclin analog) within the previous 3 months for conditions including PAH, rest pain and / or digital ulcers.
- Treatment with gemfibrozil, glitazones, or cyclophosphamide within 1 week prior to Baseline.
- Treatment with rifampin within 4 weeks prior to Baseline.
- Local injection of botulinum toxin in an affected finger within 1 month prior to Baseline.
- Received systemic antibiotics to treat infection of digital ulcers within 2 weeks prior to Baseline.
- Treatment with phosphodiesterase inhibitors such as sildenafil, except for intermittent treatment of male erectile dysfunction.
- Received an investigational product within 1 month preceding Screening.
- Known hypersensitivity to oral treprostinil or any of the excipients.
- Cigarette smoking at any level within the past 6 months prior to Screening.
- Any condition that could prevent compliance with the protocol or adherence to therapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: treprostinil diethanolamine
|
Cohort 1: Single 1 mg treprostinil diethanolamine sustained release tablet dose
Cohort 2: treprostinil diethanolamine sustained release doses will be escalated up to a target dose of 4 mg BID
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cohort 1: treprostinil pharmacokinetics in patients with systemic sclerosis following single oral administration of a 1 mg treprostinil diethanolamine SR dose.
Time Frame: pre-24hrs post dose
|
pre-24hrs post dose
|
Cohort 2: treprostinil pharmacokinetics at dose levels of 2 mg BID and 4 mg BID, respectively, in patients with systemic sclerosis following repeated oral administration of treprostinil diethanolamine SR tablets
Time Frame: 0-12 hrs post-dose
|
0-12 hrs post-dose
|
adverse event monitoring
Time Frame: Cohort 1:Day 0 to Day 2; Cohort 2: Day 0 to Day 47
|
Cohort 1:Day 0 to Day 2; Cohort 2: Day 0 to Day 47
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
clinical laboratories
Time Frame: Cohort 1: Day 0 and Day 2; Cohort 2: Day 0 and Day 47
|
Cohort 1: Day 0 and Day 2; Cohort 2: Day 0 and Day 47
|
Cohort 2: Raynauds Phenomenon Visual Analoge Scale
Time Frame: 7 weeks
|
7 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Kristan Rollins, PharmD, United Therapeutics
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2008
Primary Completion (Actual)
January 1, 2010
Study Completion (Actual)
April 1, 2010
Study Registration Dates
First Submitted
February 19, 2009
First Submitted That Met QC Criteria
February 19, 2009
First Posted (Estimate)
February 20, 2009
Study Record Updates
Last Update Posted (Estimate)
October 23, 2012
Last Update Submitted That Met QC Criteria
October 19, 2012
Last Verified
October 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TDE-DU-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Sclerosis
-
Horizon Pharma Ireland, Ltd., Dublin IrelandEnrolling by invitationDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicKorea, Republic of, France, United States, Spain, Mexico, Japan, Argentina, Greece, Israel
-
Horizon Therapeutics Ireland DACRecruitingDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicNetherlands, Spain, Germany, United States, Japan, France, Italy, Korea, Republic of, Portugal, Israel, Greece, Argentina, Austria, Mexico, Poland, Switzerland, United Kingdom, Romania, Chile
-
Michael M. PhamTerminatedSystemic Sclerosis | Scleroderma, Systemic | Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis | Interstitial Lung Disease | Scleroderma | Systemic Sclerosis, Diffuse | Diffuse Systemic Sclerosis | Pulmonary Fibrosis Interstitial | Diffuse Scleroderma | Diffuse Cutaneous Scleroderma | Progressive Systemic... and other conditionsUnited States
-
University of ManchesterCompletedEarly Diffuse Cutaneous Systemic Sclerosis
-
Fred Hutchinson Cancer CenterNational Institute of Allergy and Infectious Diseases (NIAID)CompletedSystemic Scleroderma | Severe Systemic SclerosisUnited States
-
Kadmon, a Sanofi CompanyTerminatedDiffuse Cutaneous Systemic Sclerosis | System; SclerosisUnited States
-
Boston UniversityCompleted
-
Federal University of São PauloUnknown
-
Lawson Health Research InstituteMallinckrodtNot yet recruitingDiffuse Cutaneous Systemic SclerosisCanada
Clinical Trials on treprostinil diethanolamine
-
United TherapeuticsTerminatedPulmonary Hypertension Associated With HFpEFUnited States
-
United TherapeuticsTerminatedSystemic SclerosisUnited States, Canada, United Kingdom
-
United TherapeuticsCompletedPulmonary Arterial HypertensionUnited States
-
United TherapeuticsCompletedPulmonary Arterial HypertensionUnited States, Canada, India, United Kingdom, Spain, Israel, Australia, Belgium, France, Austria, China, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Sweden
-
United TherapeuticsCompletedPulmonary HypertensionUnited States, China, Israel, Belgium, Canada, France, India, Mexico, Austria, Italy, Netherlands, Poland, Puerto Rico
-
United TherapeuticsTerminatedPulmonary Hypertension | Heart Failure With Preserved Ejection FractionUnited States
-
United TherapeuticsCompletedPulmonary Arterial Hypertension | Renal DysfunctionUnited States
-
United TherapeuticsCompletedPulmonary Arterial HypertensionUnited States
-
United TherapeuticsActive, not recruitingPulmonary Arterial HypertensionUnited States
-
United TherapeuticsCompletedPulmonary Arterial HypertensionUnited States